drugset / Trial / NCT03597009
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
Phase 1/2
Terminated
1 enrolled
UNC Lineberger Comprehensive Cancer Center
Amgen · collabC. R. Bard · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib/II clinical trial to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
Timeline
- Start
- 2019-03-06
- Primary completion
- 2020-02-07
- Completion
- 2020-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Talimogene Laherparepvec | Other / unclassified | 4 ml | Other |